Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.51 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1094337 | 0.81 | KMT2A (0.54) | SMN1; SMN2MAPTPOLBALDH1A1L3MBTL1 | |
| SCHEMBL9823526 | 0.78 | POLB (0.58) | SMN1; SMN2MAPTPOLBALDH1A1L3MBTL1 | |
| SCHEMBL8435555 | 0.78 | MAPT (0.58) | SMN1; SMN2MAPTPOLBALDH1A1L3MBTL1 | |
| SCHEMBL8435552 | 0.78 | MAPT (0.58) | SMN1; SMN2MAPTPOLBALDH1A1L3MBTL1 | |
| SCHEMBL24327745 | 0.77 | KEAP1 (0.55) | SMN1; SMN2POLBALDH1A1L3MBTL1GAA | |
| SCHEMBL29069338 | 0.77 | KEAP1 (0.41) | SMN1; SMN2ALDH1A1L3MBTL1GAAAKR1C3 | |
| SCHEMBL5040593 | 0.77 | SRC (0.46) | SMN1; SMN2MAPTALDH1A1L3MBTL1GAA | |
| SCHEMBL28194345 | 0.77 | CYP2C9 (0.46) | SMN1; SMN2POLBALDH1A1GAAKMT2A | |
| SCHEMBL155984 | 0.77 | ALDH1A1 (0.54) | SMN1; SMN2ALDH1A1L3MBTL1GAAKMT2A | |
| SCHEMBL103235 | 0.77 | ALDH1A1 (0.54) | SMN1; SMN2ALDH1A1L3MBTL1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753365-B2 | Methods of treating fibrosis | NOGRA PHARMA LIMITED (IE) | 2023-09-12 | — | — | US | disclosed |
| US-11753365-B2 | Methods of treating fibrosis | NOGRA PHARMA LIMITED (IE) | 2023-09-12 | — | — | US | disclosed |
| US-20220354809-A1 | Alkylamido Compounds and Uses Thereof | NOGRA PHARMA LIMITED (IE) | 2022-11-10 | — | — | US | disclosed |
| US-20220033346-A1 | METHODS OF TREATING FIBROSIS | NOGRA PHARMA LIMITED (IE) | 2022-02-03 | — | — | US | disclosed |
| US-11046641-B2 | Methods of treating fibrosis | NOGRA PHARMA LIMITED (IE) | 2021-06-29 | — | — | US | disclosed |
| US-20210113505-A1 | METHODS OF TREATING HAIR RELATED CONDITIONS | NOGRA PHARMA LTD (IE) | 2021-04-22 | — | — | US | disclosed |
| US-10959970-B2 | Methods of treating hair related conditions | NOGRA PHARMA LIMITED (IE) | 2021-03-30 | — | — | US | disclosed |
| US-20200383942-A1 | Alkylamido Compounds and Uses Thereof | NOGRA PHARMA LIMITED (IE) | 2020-12-10 | — | — | US | disclosed |
| EP-3744398-A1 | ALKYLAMIDO COMPOUNDS AND USES THEREOF | Nogra Pharma Limited (IE) | 2020-12-02 | — | — | EP | disclosed |
| US-20200188340-A1 | Methods of Treating Hair Related Conditions | GIULIANI INTERNATIONAL, LTD. (IE) | 2020-06-18 | — | — | US | disclosed |
| US-20090048343-A1 | Compounds and Their Salts Specific to the PPAR Receptors and the EGF Receptors and Their Use in the Medical Field | NOGRA PHARMA LIMITED (IE) | 2009-02-19 | — | — | US | disclosed |
| CN-101243039-A | PPAR receptor and EGF receptor specific compounds and salts thereof and their use in the medical field | GIULIANI INT LTD (IE) | 2008-08-13 | — | — | CN | disclosed |
| EP-1910270-A2 | COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD | Giuliani International Limited (IE) | 2008-04-16 | — | — | EP | disclosed |
| EP-1567498-B1 | MANDELIC ACID DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-01-23 | — | — | EP | disclosed |
| WO-2007010516-A2 | COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD | GIULIANI INTERNATIONAL LIMITED (IE) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007010516-A2 | COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD | GIULIANI INTERNATIONAL LIMITED (IE) | 2007-01-25 | — | — | WO | disclosed |
| US-7129238-B2 | Mandelic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-10-31 | — | — | US | disclosed |
| EP-1567498-A2 | MANDELIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-08-31 | — | — | EP | disclosed |
| US-20040122057-A1 | Novel mandelic acid derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-24 | — | — | US | disclosed |
| WO-2004048335-A2 | MANDELIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220354809-A1 | Alkylamido Compounds and Uses Thereof | EGFR, PPARG, ERBB3 | SMN1; SMN2 4752/4885MAPT 4821/4885POLB 1835/4885 |
| US-20200383942-A1 | Alkylamido Compounds and Uses Thereof | EGFR, PPARG, ERBB3 | SMN1; SMN2 4752/4885MAPT 4821/4885POLB 1835/4885 |
| US-20040122057-A1 | Novel mandelic acid derivatives | F7, F11, F9 | SMN1; SMN2 3242/4885MAPT 4423/4885POLB 4478/4885 |
| US-11753365-B2 | Methods of treating fibrosis | MMP1, MMP8, FABP2 | SMN1; SMN2 3152/4885MAPT 4649/4885POLB 2470/4885 |
| US-20210113505-A1 | METHODS OF TREATING HAIR RELATED CONDITIONS | EBP, AADAT, ALDH7A1 | SMN1; SMN2 3829/4885MAPT 3856/4885POLB 1728/4885 |
| US-20090048343-A1 | Compounds and Their Salts Specific to the PPAR Receptors and the EGF Receptors and Their Use in the Medical Field | EGFR, ERBB3, FGFR3 | SMN1; SMN2 4805/4885MAPT 4794/4885POLB 2776/4885 |
| US-10959970-B2 | Methods of treating hair related conditions | PPARA, PPARG, PPARD | SMN1; SMN2 4815/4885MAPT 3873/4885POLB 1451/4885 |
| US-20200188340-A1 | Methods of Treating Hair Related Conditions | PPARA, PPARG, PPARD | SMN1; SMN2 4815/4885MAPT 3873/4885POLB 1451/4885 |
| US-11046641-B2 | Methods of treating fibrosis | MMP1, MMP8, FABP2 | SMN1; SMN2 3152/4885MAPT 4649/4885POLB 2470/4885 |
| US-20220033346-A1 | METHODS OF TREATING FIBROSIS | MMP1, MMP8, FABP2 | SMN1; SMN2 3152/4885MAPT 4649/4885POLB 2470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.